Besides, the company offers PK or anti-drug antibodies (ADA) antibody preparation services, immunogenicity assays for multispecific antibodies, and serum concentration analysis, thus assisting ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin gamma monoclonal antibodies (hIgG mAbs) are a most promising biological therapy for treating an ...

Interim results concerning safety, PK and pharmacodynamic (PD ... Phase I results for our next-generation anti-α4β7 antibody, SPY001, which exhibited a greater than 90-day half-life enabling ...

Chinese researchers have found a neutralizing antibody that could provide protection against the Delta and Omicron variants of Covid-19, and it has shown preventative efficacy by nasal delivery.

About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to assess the safety, tolerability ...

InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, together with their joint venture, have jointly entered into an exclusive ...